Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2023-02-27 Earnings Release
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
2022年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled '2022 年度业绩快报公告' which translates to '2022 Annual Performance Express Report Announcement'. It contains preliminary financial data for the year 2022, explicitly stating that the data is unaudited and subject to the final annual report. The document is relatively short (1707 characters) and emphasizes that the final audited data will be in the 2022 annual report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only, not the full audited report. It is not the full Annual Report (10-K) because it lacks comprehensive audited financial statements and detailed analysis. It is also not a Report Publication Announcement (RPA) because it contains substantive financial data, not just a notice of report availability. Therefore, the correct classification is Earnings Release (ER). FY 2022
2023-02-27 Chinese
自愿披露关于HP530S片获得药物临床试验申请受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company HaiChuang Pharmaceutical Co., Ltd. regarding the acceptance of a clinical trial application for a drug named HP530S. It includes details about the drug, its clinical trial application acceptance by the National Medical Products Administration, and risk warnings related to drug development. The document is short (1327 characters) and is an announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial data, earnings, management changes, or other report types. It is a regulatory announcement about a clinical trial acceptance, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-02-09 Chinese
自愿披露关于HP501缓释片获得药物临床试验申请受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving a clinical trial application acceptance notice from the National Medical Products Administration. It details the drug HP501, its clinical trial status, and related regulatory information. The document is short (1524 characters) and serves as an announcement of a regulatory event rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types defined. It is a regulatory announcement about a clinical trial acceptance, fitting best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2023-02-03 Chinese
自愿披露关于PROTAC药物HP518临床试验申请获得FDA批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about receiving FDA approval for a clinical trial application of a new drug. It contains no financial data, no detailed financial statements, nor any report-like content. It is a regulatory announcement about a significant event related to the company's drug development. The document length is short (1136 characters), and it is clearly an announcement of an event rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-01-31 Chinese
2022年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2022 annual performance forecast (业绩预告) for the full year 2022, providing preliminary estimated net profit figures and explanations for the changes compared to the prior year. It explicitly states that the forecast is unaudited and preliminary, and that the final audited annual report will be published later. The document length is short (1088 characters) and it is clearly a performance forecast, not a full annual report or audited financial statement. This type of document is typically classified as an Earnings Release (ER) because it announces key financial results highlights for a fiscal year before the full annual report is available. FY 2022
2023-01-20 Chinese
关于《专利实施许可协议及相关协议之解除协议》的交易进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the company 海创药业股份有限公司 regarding the progress of a transaction related to the termination of a patent license agreement and related agreements. It details the background of the agreements, the payment arrangements, and clinical trial progress updates. The document is relatively short (1369 characters) and focuses on transaction progress and corporate disclosures rather than presenting full financial statements or detailed financial analysis. It does not contain comprehensive financial data or management discussion typical of annual or interim reports. It is not a call transcript, audit report, or governance information. The content fits best with a Capital/Financing Update (CAP) as it discusses payment arrangements and transaction progress related to licensing agreements and commercialization efforts. Therefore, the appropriate classification is CAP with high confidence.
2022-12-30 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.